As the end of the second quarter of 2020 approaches, a number of biopharmaceutical companies have data readouts due – and positive trial data could serve as catalysts for those companies’ stocks. For seven biopharmaceutical companies with impending data readouts – and details on their respective potential catalysts – CLICK HERE.
March 2020 was not the worst-performing month in stock market history, but it was the craziest month in stock market history, according to the author of today’s article. That is, if crazy is defined by monthly market volatility. In fact, he notes that in terms of one particular measure of volatility, “March 2020 wasn’t just a little crazier than the next 3 highest months…it was significantly crazier.” For more on how March was the craziest month ever for equities – and other assets classes – CLICK HERE.
“It may be nice to look back at the gains of the last year, several years or decade, but it’s the look out into 2020 and beyond that will matter the most for any investor who is not yet in retirement,” notes the author of today’s article after reviewing the strong stock market gains of 2019. So can those gains continue? In order to assess this, he provides “a review and preview of issues impacting 2019 and looking into 2020”, examining the risks and opportunities involved in the stock market in general as well as in specific companies. For more, CLICK HERE.